Cargando…

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study

BACKGROUND: Retrospective studies suggest that low molecular weight heparin may delay the development of metastasis in patients with resected NSCLC. METHODS: Multicentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive chemotherapy with or witho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groen, Harry J. M., van der Heijden, Erik H. F. M., Klinkenberg, Theo J., Biesma, Bonne, Aerts, Joachim, Verhagen, Ad, Kloosterziel, Corinne, Pieterman, Remge, van den Borne, Ben, Smit, Hans J. M., Hoekstra, Otto, Schramel, Frans M. N. H., van der Noort, Vincent, van Tinteren, Harm, Smit, Egbert F., Dingemans, Anne-Marie C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738047/ https://www.ncbi.nlm.nih.gov/pubmed/31337877 http://dx.doi.org/10.1038/s41416-019-0533-3

Ejemplares similares

Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial
por: Brouns, Anita J. W. M., et al.
Publicado: (2020)

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
por: Verduyn, S Cora, et al.
Publicado: (2012)

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
por: de Jong, Evelyn E. C., et al.
Publicado: (2016)

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis
por: Buitenwerf, Edward, et al.
Publicado: (2015)

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
por: Wachters, F M, et al.
Publicado: (2005)

Effectiveness and Safety of Nadroparin Therapy in Preterm and Term Neonates with Venous Thromboembolism
por: Sol, Jeanine, et al.
Publicado: (2021)

Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
por: Diepstraten, Jeroen, et al.
Publicado: (2022)

Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study
por: van der Veen, Lucia, et al.
Publicado: (2021)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
por: Wilhelmy, Florian, et al.
Publicado: (2021)

The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin
por: Sytema, Jelmer G., et al.
Publicado: (2023)

Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy
por: Huisman, C, et al.
Publicado: (2001)

Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design
por: Gurfinkel, Enrique P, et al.
Publicado: (2004)

The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
por: Debergh, I, et al.
Publicado: (2010)

Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury
por: Eck, R. J., et al.
Publicado: (2022)

‘Care for Outcomes’: systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer
por: Cramer-van der Welle, Christine M, et al.
Publicado: (2021)

Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [(11)C]docetaxel
por: van der Veldt, Astrid A. M., et al.
Publicado: (2013)

Nadroparin calcium: Spontaneous retroperitoneal bleeding: 2 case reports
Publicado: (2022)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
por: Romano, Lorenzo G. R., et al.
Publicado: (2022)

An invisible group of COVID-19 victims; impact on Dutch lung cancer care
por: van Breeschoten, Jesper, et al.
Publicado: (2021)

Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series
por: Russcher, Marije, et al.
Publicado: (2013)

The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients
por: Mast, L., et al.
Publicado: (2023)

Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models
por: Zhuang, Xibing, et al.
Publicado: (2018)

Comment on Cho et al.: Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction
por: van der Veldt, Astrid A. M., et al.
Publicado: (2011)

Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels
por: Jaspers, Tessa C. C., et al.
Publicado: (2022)

Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer
por: Cramer‐van der Welle, Christine M., et al.
Publicado: (2020)

Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
por: Kerner, Gerald SMA, et al.
Publicado: (2014)

Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)
por: Phernambucq, E C J, et al.
Publicado: (2006)

Rare complication of nadroparin injections: Skin necrosis and heparin‐induced thrombocytopenia syndrome
por: Malinauskiene, Laura, et al.
Publicado: (2022)

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism
por: Xiong, Wei, et al.
Publicado: (2022)

Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
por: Derks, Jules L., et al.
Publicado: (2017)

Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions
por: Hummelink, Karlijn, et al.
Publicado: (2019)

Orthology prediction at scalable resolution by phylogenetic tree analysis
por: van der Heijden, René TJM, et al.
Publicado: (2007)

Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA)
por: van Veen, Lucia, et al.
Publicado: (2013)

Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome
por: Kerner, Gerald S. M. A., et al.
Publicado: (2013)

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005)

Nadroparine-induced skin necrosis on a patient with essential thrombocythaemia: a case report
por: Pramateftakis, Manousos-Georgios, et al.
Publicado: (2009)

Fondaparınux Versus Nadroparın for Preventıon of Venous Thromboembolısm After Electıve Hıp and Knee Arthroplasty()
por: Argun, Mahmut, et al.
Publicado: (2013)

Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19
por: Piwowarczyk, Paweł, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c34cj4ggj6fc5pdbqp6554vvfd